CTLA4 and hepatocellular carcinoma: Immunotherapies targeting programmed death‐1 (PD‐1) and cytotoxic T‐lymphocyte‐associated antigen 4 (CTLA‐4) are becoming effective novel treatment strategies for HCC.28, 29, 53